Logo

AbbVie Enters into a Collaboration to Develop Monoclonal Antibody Therapy for Preventing COVID-19

Share this

AbbVie Enters into a Collaboration to Develop Monoclonal Antibody Therapy for Preventing COVID-19

Shots:

  • AbbVie collaborated with Harbour BioMed (HBM)- Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a novel Ab to prevent and treat COVID-19. The collaboration focuses on advancing 47D11- discovered by UU- EMC and HBM that targets the domain of the spike protein of SARS-CoV-2
  • AbbVie will support UU- EMC- and HBM in preclinical activities- while simultaneously preparing late-stage pre/ clinical development. AbbVie to get an option to exclusively license the Ab from the three parties for WW clinical development and commercialization
  • The Ab discovered by UU- EMC- and HBM is based on the mechanism by which it targets the virus and on its developability as a fully human protein. The is designed to facilitate its development and minimize immune-related side effects

Click here to read full press release/ article 

Ref: AbbVie | Image: AbbVie


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions